Jeffrey Weber, MD
Medical Oncology · Tampa, FLNPI 1053348706
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $153,117 of the $193,319 with a category attached, or 79.2%. 16 manufacturers reported payments, led by Merck at 33.8% of the total. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $1333.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$65K
- Novartis$27K
- E.r. Squibb & Sons, L.L.C.$18K
- Regeneron$17K
- Modernatx, Inc.$11K
- Incyte Corporation$10K
- plus $45K from 10 others
Across 231 payments — averaging $14,776 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.4M
- Modernatx, Inc.$728K
- Merck$435K
- Alkermes, Inc.$212K
- GSK$205K
- Novartis$194K
- plus $199K from 3 others
What the payments were for
- Consulting fees$153,11779%
- Speaking & faculty fees$11,1246%
- Travel & lodging$27,33414%
- Food & beverage$1,7441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 57 | $65,395 |
| Novartis | 20 | $26,556 |
| E.r. Squibb & Sons, L.L.C. | 14 | $18,006 |
| Regeneron | 7 | $16,896 |
| Modernatx, Inc. | 15 | $10,827 |
| Incyte Corporation | 7 | $10,455 |
| Astrazeneca UK Limited | 3 | $9,590 |
| Alkermes, Inc. | 9 | $9,394 |
| Bristol Myers Squibb | 2 | $5,645 |
| GSK | 2 | $5,234 |
| Array Biopharma Inc | 4 | $5,116 |
| Astellas Pharma Inc | 1 | $2,910 |
| Jazz Pharmaceuticals Inc. | 1 | $2,250 |
| Genentech, Inc. | 1 | $2,145 |
| Pfizer | 1 | $2,000 |
| AbbVie | 1 | $900 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,319 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
- Boris NaraevTampa$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.